Sugi Predict

Sugi Predict / Compounds / SCHEMBL5401611

SCHEMBL5401611

SCHEMBL5401611

Nc1ccc2c(cnn2C2CCCCO2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.58
▸ RXRB P28702 1/20 0.58
▸ RXRG P48443 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.50
▸ LMNA P02545 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ CHEK1 O14757 1/20 0.43
▸ AURKA O14965 1/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ CSNK1A1 P48729 1/20 0.43
▸ GSK3A P49840 1/20 0.43
▸ LIMK1 P53667 1/20 0.43
▸ IKBKE Q14164 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ TAOK1 Q7L7X3 1/20 0.43
▸ CLK4 Q9HAZ1 1/20 0.43
▸ DYRK1B Q9Y463 1/20 0.43
▸ CYP4F2 P78329 5/20 0.40
▸ CYP4A11 Q02928 5/20 0.40
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30162982 1.00 RXRA (0.58) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL30442483 0.89 ALDH1A1 (0.50) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL2144678 0.89 ALDH1A1 (0.50) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL16569539 0.84 RXRA (0.61) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL767811 0.84 RXRA (0.58) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL10172904 0.84 RXRA (0.58) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL29926106 0.84 RXRA (0.61) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL770688 0.84 RXRA (0.58) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL658009 0.84 RXRA (0.58) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL3640296 0.83 RXRA (0.64) RXRARXRBRXRGALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 — — US disclosed
EP-4678634-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF Haihe Biopharma Co., Ltd. (CN) 2026-01-14 — — EP disclosed
EP-4387963-B1 PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 REDX PHARMA LTD (GB) 2025-12-24 — — EP disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 — — US disclosed
US-20250115577-A1 BCL-2 Inhibitors Eil Therapeutics, Inc. 2025-04-10 — — US disclosed
US-20240368132-A1 ROCK2 INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-11-07 — — US disclosed
EP-4457223-A1 BCL-2 INHIBITORS Eil Therapeutics, Inc. (US) 2024-11-06 — — EP disclosed
WO-2024183793-A1 ANDROGEN RECEPTOR MODULATORS AND USES THEREOF 上海海和药物研究开发股份有限公司 2024-09-12 — — WO disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 — — US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 — — US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 — — US disclosed
WO-2014033448-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS RESPIVERT LIMTED (GB) 2014-03-06 — — WO disclosed
WO-2014033448-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS RESPIVERT LIMTED (GB) 2014-03-06 — — WO disclosed
WO-2013071217-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2013-05-16 — — WO disclosed
EP-2240467-B1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG (DE) 2013-03-20 — — EP disclosed
US-20130045973-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG 2013-02-21 — — US disclosed
WO-2009089057-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INS. (US) 2009-07-16 — — WO disclosed
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 — — US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 — — US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045973-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 RXRA 1304/4885RXRB 1339/4885RXRG 922/4885
US-20240368132-A1 ROCK2 INHIBITORS AND USES THEREOF ROCK2, ROCK1, RHOA RXRA 2570/4885RXRB 1969/4885RXRG 1600/4885
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA RXRA 4599/4885RXRB 4513/4885RXRG 4517/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA RXRA 2845/4885RXRB 2693/4885RXRG 2410/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA RXRA 2845/4885RXRB 2693/4885RXRG 2410/4885
US-20140315911-A1 DIHYDROPTERIDINONES DHPS, DHODH, HYPK RXRA 3134/4885RXRB 2409/4885RXRG 2791/4885
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA RXRA 1096/4885RXRB 1324/4885RXRG 1147/4885
US-20250115577-A1 BCL-2 Inhibitors BCL2, BCL2L1, BCL2L2 RXRA 2930/4885RXRB 2487/4885RXRG 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.